Discover how the FDA's approval of Vetmedin, the first drug to delay congestive heart failure in dogs, is transforming canine ...
The MarketWatch News Department was not involved in the creation of this content. -- Heart disease affects approximately 10 percent of dogs in their lifetime1 -- VETMEDIN(R) (pimobendan) from ...
Canine mitral valve disease, most commonly stemming from myxomatous degeneration, is the predominant acquired cardiac condition in dogs. This disease is characterised by progressive deterioration of ...
Heart disease affects approximately 10 percent of dogs in their lifetime1 VETMEDIN® (pimobendan) from Boehringer Ingelheim is the only medication approved to treat preclinical mitral valve disease in ...
Jan 19 (Reuters) - Pharmaceutical company Boehringer Ingelheim said on Monday the U.S. Food and Drug Administration had approved its chewable tablet, as the first drug to delay congestive heart ...
DULUTH, Ga., Jan. 19, 2026 /PRNewswire/ -- Boehringer Ingelheim, a global leader in animal health, today announced that the U.S. Food and Drug Administration (FDA) has approved VETMEDIN (pimobendan) ...
Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results